Megan Hollasch

Articles

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

January 27th 2024

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Preclinical Study Reveals Potential Role for GLP Agonists in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Vice President of ASH Will Focus on Gene Therapies, ASH’s Global Impact

January 24th 2024

The field of hematology is experiencing significant advancements as promising new therapies for malignancies and GVHD continue to emerge.

Laying the Foundation for an Improved HR+/ HER2- Breast Cancer Treatment Paradigm

January 22nd 2024

Investigators continue to evaluate HER2 expression as well as CDK4/6 inhibitor use for hormone receptor–positive/HER2-negative breast cancer.

ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers

January 18th 2024

ASKB589 demonstrated anti-tumor activity in combination with capecitabine and oxaliplatin plus sintilimab in gastric or gastroesophageal junction cancers.

AURKA Pathway Gains Ground as Targetable Option in Metastatic Breast Cancer

January 17th 2024

As novel drugs targeting the AURKA pathway continue to advance through the development pipeline, alisertib has emerged as an agent of particular note.

Lonial Reviews 2023 Highlights for Multiple Myeloma, Forecasts 2024 Research Interests

January 16th 2024

Sagar Lonial, MD, FACP, details agents of interest outside CAR T-cell therapies in multiple myeloma, including elranatamab and talquetamab.

Discovering Fusions Requires More Than DNA Testing in GI Cancers

January 16th 2024

E. Gabriela Chiorean, MD, highlights the importance of consistently testing for biomarkers with RNA-based tests in addition to DNA-based tests.

First-in-Class YAP/TEAD Inhibitor Demonstrates Early Efficacy Targeting Hippo Pathway

January 11th 2024

Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway by inhibiting the transcription function of TEAD-YAP.function of TEAD-YAP.

Wakelee Addresses NSCLC Treatment Considerations From Every Angle

January 10th 2024

Heather Wakelee, MD, discusses the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.

Knocking Expectations Out of the Park in the Search for a Cure

December 31st 2023

Dedication to his patients and the field of hematology spanning decades has led Stephen J. Forman, MD, to break down barriers for treating patients with leukemia and lymphoma.

Alisertib Induces Early Signals of Efficacy in Endocrine-Resistant Breast Cancer

December 22nd 2023

Alisertib as monotherapy and in combination with fulvestrant stands at the forefront of the clinical investigation of selective AURKA pathway inhibition in patients with endocrine-resistant advanced breast cancer, according to Tufia C. Haddad, MD.

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

December 11th 2023

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer

December 7th 2023

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki demonstrated encouraging antitumor activity in patients with chemotherapy-naïve, HER2-low hormone receptor–positive metastatic breast cancer.

BDTX-1535 Strives to Overcome Intrinsic and Acquired EGFR Mutations in NSCLC and GBM

December 4th 2023

Patients with non–small cell lung cancer harboring acquired EGFR mutations, such as C797S and intrinsic mutations in EGFR represent underserved populations where additional targeted therapies are needed.

TKI and Immunotherapy Combo Efforts in RCC Remain of Interest as Treatment Arsenal Evolves

December 4th 2023

Final outcomes from the phase 1b/2 Study 111/KEYNOTE-146 trial, evaluating treatment with lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma, has sparked interest in the use of this combination.

AON Joins Nasdaq to Further Patient-Centric Community Oncology Care

November 25th 2023

The American Oncology Network has started trading on Nasdaq with the goal of continuing the growth of the organization.

New Data From 2023 ESMO Congress Further Define the Evolving Role of ADCs in NSCLC

November 15th 2023

With a plethora of data coming out of the 2023 European Society for Medical Oncology Congress, findings from multiple clinical trials examining antibody-drug conjugates in non–small cell lung cancer demonstrated encouraging antitumor activity and manageable safety profiles, including results from the phase 3 TROPION-Lung01 study, which evaluated datopotamab deruxtecan vs docetaxel in pretreated patients with advanced or metastatic disease.

OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC

November 13th 2023

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.

IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

November 11th 2023

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.